Patients with inflammatory bowel disease and other immune-mediated diseases treated with anti-TNF alpha who previously had cancer are not at greater risk for recurrent or new primary cancers, according to the results of a population-based study.“Historically, clinicians have been concerned about whether [anti-TNF alpha] therapies predispose people to cancer, resulting in a reluctance to prescribe these medications to patients with a history of cancer,” Akbar K. Waljee, MD, of the division of gastroenterology and hepatology at the University of Michigan, and colleagues wrote. “BecauseRead More